CRVO CERVOMED INC

CervoMed to Participate in Upcoming Investor Conferences

CervoMed to Participate in Upcoming Investor Conferences

BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that Company management will participate in the following investor conferences during the month of March:

Leerink Global Healthcare Conference

Format: 1x1 Investor Meetings

Date: Wednesday, March 11, 2026

38th Annual ROTH Conference

Format: Fireside Chat & 1x1 Investor Meetings

Presentation Date: Monday, March 23, 2026

Presentation Time: 12:00 – 12:30 PM PT

The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website

About CervoMed

CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in DLB patients who have a low likelihood of AD co-pathology, and the Company plans to initiate a global, pivotal Phase 3 trial in the same patient population in the second half of 2026, subject to available funding.

Contacts:

Media:

Lisa Guiterman

Biongage Communications



202-330-3431

Investor Relations:

Argot Partners



212-600-1902 



EN
05/03/2026

Underlying

CRVOCERVOMED INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CERVOMED INC

 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results a...

CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates Reported positive Phase 2b RewinD-LB clinical data at CTAD 2025; additional analyses to be presented at AD/PD 2026 Obtained alignment with FDA and global regulators for planned Phase 3 trial design in patients with DLB and selected Phase 3 formulation, dose and dosing regimen Multiple potential catalysts anticipated in the second half of 2026, including initiation of the planned Phase 3 trial, topline data from Phase 2a ischemic stroke recovery trial, initial topline data from Phase 2a prim...

March 17, 2026 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Co...

CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference Data further support choice of patient population and dosing regimen in CervoMed's planned Phase 3 trial in dementia with Lewy bodies (DLB) DLB is the second most common progressive dementia, affecting millions worldwide, and has no approved treatments in the United States or European Union BOSTON, March 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (CervoMed or the Company), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that neflamap...

March 12, 2026 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed to Participate in Upcoming Investor Conferences

CervoMed to Participate in Upcoming Investor Conferences BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that Company management will participate in the following investor conferences during the month of March: Leerink Global Healthcare Conference Format: 1x1 Investor MeetingsDate: Wednesday, March 11, 2026 38th Annual ROTH ConferenceFormat: Fireside Chat & 1x1 Investor MeetingsPresentation Date: Monday, March 23, 2026Presentation Time: 12:00 – 12:30 PM ...

March 5, 2026 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed Announces Selection of Formulation and Dosing Regimen for Pla...

CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies Bioavailability data recently obtained from Phase 1 study with a stable crystal form of neflamapimod manufactured using a new, controlled manufacturing process Pharmacokinetic profile of the new, stable crystal form of neflamapimod largely overlaps with the therapeutically active drug product used in Phase 2b trial extension To ensure that plasma drug concentrations associated with therapeutic activity are achieved, dosing regimen in the planned Phase 3 trial...

March 4, 2026 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platfo...

CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis Neflamapimod endorsement based on targeted mechanism of action, demonstrated clinical activity in neurodegenerative diseases, and encouraging translational data in ALS-relevant neurotoxicity models UK-based trial first to evaluate neflamapimod in ALS; first person with ALS expected to be dosed by end of 2026 Trial costs funded by United Kingdom government and leading motor neuron disease charities BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -...

February 18, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch